Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Genital Diseases, Male 1Carcinoma 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
palladium-bacteriopheophorbide × Clear all
NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡